Identification of CCL1 as a Gene Differentially Expressed in CD4+ T Cells Expressing TIM-3

Ka Jung Jun; Mi Jin Lee; Dong Chul Shin; Min Yeong Woo; Kyongmin Kim; Sun Park

doi:10.4110/in.2011.11.4.203

Journal List > Immune Netw > v.11(4) > 1033294

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Jun, Lee, Shin, Woo, Kim, and Park: Identification of CCL1 as a Gene Differentially Expressed in CD4+ T Cells Expressing TIM-3

Original Article

Immune Network

Immune Network 2011; 11(4): 203-209.

Published online: 31 August 2011

DOI: https://doi.org/10.4110/in.2011.11.4.203

Identification of CCL1 as a Gene Differentially Expressed in CD4⁺ T Cells Expressing TIM-3

Ka Jung Jun^1,², Mi Jin Lee^1,², Dong Chul Shin^1,², Min Yeong Woo^1,², Kyongmin Kim¹, Sun Park¹

¹Department of Microbiology, Ajou University School of Medicine, Suwon 442-749, Korea.

²Graduate Program of Molecular Medicine, Ajou University School of Medicine, Suwon 442-749, Korea.

Corresponding Author. Tel: 82-31-219-5070; Fax: 82-31-219-5079; sinsun@ajou.ac.kr

Received 23 June 2011 Revised 9 July 2011 Accepted 15 July 2011

(open-access):

This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

T cell immunoglobulin mucin containing molecule (TIM)-3 is expressed in differentiated Th1 cells and is involved in the suppression of the cytokine production by these cells. However, the regulation of the expression of other T cell genes by TIM-3 is unclear. Herein, we attempted to identify differentially expressed genes in cells abundantly expressing TIM-3 compared to cells with low expression of TIM-3.

Methods

TIM-3 overexpressing cell clones were established by transfection of Jurkat T cells with TIM-3 expression vector. For screening of differentially expressed genes, gene fishing technology based on reverse transcription-polymerase chain reaction (RT-PCR) using an annealing control primer system was used. The selected candidate genes were validated by semi quantitative and real-time RT-PCR.

Results

The transcription of TIMP-1, IFITM1, PAR3 and CCL1 was different between TIM-3 overexpressing cells and control cells. However, only CCL1 transcription was significantly different in cells transiently transfected with TIM3 expression vector compared with control cells. CCL1 transcription was increased in primary human CD4⁺ T cells abundantly expressing TIM-3 but not in cells with low expression of TIM-3.

Conclusion

CCL1 was identified as a differentially transcribed gene in TIM-3-expressing CD4⁺ T cells.

Keywords: TIM-3, Gene expression, CD4⁺ T cell, CCL1

INTRODUCTION

TIM-3 is a transmembrane protein containing immunoglobulin V like domain, mucin domain, transmembrane domain and cytoplasmic domain. TIM-3 plays important roles in immune responses and the pathogenesis of several diseases (1). With its blocking antibody or its soluble fusion protein TIM-3-Ig, Th1 immune response as well as anti-tumor immunity is enhanced (2-4). Also, induction of tolerance in an experimental transplantation model is abrogated by injection of TIM-3 antibody (5). Furthermore, dysregulation of T cell TIM-3 expression is observed in several autoimmune diseases including multiple sclerosis, rheumatoid arthritis and Crohn's disease (6-8).

Galectin-9 and phosphatidylserine have been identified as TIM-3 ligands. Galectin-9 was originally identified as a potent eosinophil chemoattractant produced and released by antigen-stimulated T cells (9). Galectin-9 induces intracellular calcium flux, aggregation and death of in vitro cultured Th1 cells in a manner that is dependent on Tim-3, and administration of galectin-9 in vivo results in selective loss of interferon-gamma-producing cells and suppression of Th1 autoimmunity (10). In the other hand, phosphatidylserine, which is normally localized to the inner leaflet of the plasma membrane, is exposed on the cell surface when the cell is activated or undergoes apoptosis. TIM-3 on monocytes and dendritic cells binds phosphatidylserine on apoptotic cells and enhances presentation of antigen expressed in the apoptotic cells through the upregulation of endocytosis (11).

In this study, we wanted to identify the genes that were differentially expressed in T cells by TIM3 expression. Using TIM3 overexpressing Jurkat T cell lines and panels of degenerate primer sets we found three genes (TIMP-1, IFITM1 and CCL1) that were up-regulated in TIM3 overexpressing cells, and one gene (PAR3) that was down-regulated in TIM3 overexpressing cells. However, only the CCL1 transcript level was significantly increased in Jurkat T cells transiently transfected with TIM3 expression vector as well as in human primary CD4⁺ T cells expressing abundantly TIM-3.

MATERIALS AND METHODS

Cells and stimulation

The human Jurkat T cell line was cultured in RPMI1640 medium (Gibco BRL, Paisley, Scotland) supplemented with 10% fetal bovine serum (FBS; Gibco BRL), 100 U/ml penicillin and 100µg/ml streptomycin (Gibco BRL) at 37℃ in 5% CO₂ incubator.

Construction of plasmids for expression of flag tagged TIM3

The human TIM-3 gene was cloned from peripheral blood mononuclear cells (PBMCs) stimulated with concanavalin A (ConA; 1µg/ml) for 2 days. Total RNA was subjected to reverse transcription-polymerase chain reaction (RT-PCR) using the human TIM-3 specific primers [HTIM3F(KpnI) 5'-GGGGTACCGTTAAAACTGTGCCTAACAG-3', HTIM3R(Hind III): 5'-CCCAAGCTTCAAAAATAAGGTGGTTGG-3'] and then cloned into a pGEM-T vector (Promega, Madison, WI, USA). The TIM3 gene amplified with specific primers [TIM3(Xho I): 5'-CCGCTCGAGTACGAAGTGGAATACAGAGCG GAGG-3' and TIM3(Xma I): 5'-TCCCCCCGGGCTATGGCATTGCAAAGCGACAAC-3'] was inserted into a pIRES2-EGFP vector (Clontech Laboratories, Mountain View, CA, USA). The DNA fragment for leader and flag peptide was inserted upstream of the TIM-3 gene at Nhe I and Xho I sites. The nucleotide sequences were verified.

Establishment of stable cells expressing TIM-3 protein

The pIRES2-EGFP-TIM3 vector or empty vector was transfected into Jurkat T cells using the Microporator (Digital Bio Technology, Seoul, Korea) with settings of 1200 V, pulse width 20 and pulse number 1. Among the clones resistant to neomycin, two independent clones (T5 and T7) that expressed TIM-3 on the surface and green fluorescence protein (GFP) in the cytoplasm were selected by flow cytometry. As controls, two independent clones expressing GFP alone were selected (G2 and G6).

Flow cytometry

For TIM-3 detection, cells were labeled with anti-human TIM-3-PE (R&D Systems, Minneapolis, MN, USA) and analyzed using a FACSCanto II apparatus (Becton Dickinson, San Diego, CA, USA).

Screening of differentially expressed genes using annealing control primer (ACP) system

Total RNAs of T5 and G2 were extracted using a RNA isolation kit RNAiso (TaKaRa Bio, Shiga, Japan). cDNA synthesis and RT-PCR were performed following the procedures recommended by the manufacturer using an annealing control primer system (Seegene, Seoul, Korea). PCR products were analyzed by agarose gel electrophoresis. Differentially amplified PCR products eluted from gel were cloned into a pCR2.1-TOPO vector (Invitrogen, Carlsbad, CA, USA) and then sequenced. The identical DNA sequence to the insert was searched using BLASTN.

Semiquantitive RT-PCR and real-time RT-PCR

To validate the transcription level of the selected genes, semiquantitive RT-PCR was performed using a specific primer set for each gene (Table I). CCL1 transcription level was assessed by real-time RT-PCR using Sybr Premix Ex Taq (TaKaRa, Shiga, Japan). The CCL1 primers (Bioneer, Daejeon, Korea) were 5'-AATACCAGCTCCATCTGCTCCAA-3' and 5'-GAACCCATCCAACTGTGTCCAAG-3'. CCL-1 transcription was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) transcription.

Isolation of primary CD4⁺ T cells and TIM-3^high T cells

Primary human CD4⁺ T cells were isolated from peripheral blood mononuclear cells of healthy donors using magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany). The cells were stimulated with antibodies against CD3 (1µg/ml) and CD28 (1µg/ml) for 7 days and then sorted into TIM-3 high and TIM-3 low cells by fluorescence activated cell sorting using a FACS Aria II cell sorter (BD, Franklin Lakes, NJ) after labeling with allophycocyanin (APC)-conjugated anti-TIM-3 antibody (eBioscience, San Diego, CA). All blood samples were obtained in compliance with the Ajou University Institutional Review Board protocol.

Statistics

Student's t-test was done with a p value<0.05 being considered significant.

RESULTS

Jurkat T cell clones over-expressing TIM-3

To identify the genes that were differentially expressed in T cells by TIM-3 expression, we established cell lines overexpressing TIM-3 by stably transfecting Jurkat T cells with an expression vector containing TIM-3 gene under the control of the cytomegalovirus promoter as well as a gene for GFP under the internal ribosome entry site. Cells expressing GFP were sorted twice using fluorescence activated cell sorting (FACS) and then cloned. Compared to parental Jurkat T cells and GFP expressing clones (G2 and G6), TIM-3 expression in the T5 and T7 stable cell clones was clearly demonstrated (Fig. 1).

The differentially expressed gene candidates by TIM-3 expression

To screen for differentially expressed genes in TIM-3 expressing cells, RNA was isolated from Jurkat T cells, T5 cells stimulated with phorbol 12-myristate 13-acetate (PMA) and A23187, and then RT-PCR was performed using an ACP system. Agarose gel electrophoresis selected 76 PCR products showing up- or down-regulated expression in T5 compared to Jurkat T cells for sequencing (Fig. 2). Sequence analysis of these genes showed that several PCR products with different ACP sets overlapped. Eleven differentially expressed gene candidates were identified by homology search using the NCBI dbEST database (Table II).

Validation of difference in transcription of the candidate genes

To validate the candidate gene expression levels, semi-quantitative RT-PCR was conducted using sequence specific primers and RNA isolated from Jurkat T cells, G2, G6, T5 and T7 (Fig. 3). The transcription of TIMP-1, IFITM1 and CCL1, respectively, was increased in T5 and T7 cells, compared to control cells. CCL1 expression was induced in all cells when stimulated; the induction level was greater in T5 and T7 cells than in control cells. In contrast, the transcription of PAR3 was reduced in T5 and T7 cells compared to control cells. Next, the transcript levels of these genes were assessed in cells transiently transfected with TIM3 expression vector (Fig. 4). Only the CCL1 transcript level was significantly increased in cells transiently transfected with TIM3 expression vector compared with control cells (p<0.05).

The increased transcription of CCL1 in human primary CD4⁺ T cells highly expressing TIM-3

Finally we examined the transcription of CCL1 in primary CD4⁺ T cells highly expressing TIM-3 (Fig. 5). CD4⁺ T cells isolated from human subjects were stimulated for 7 days and then sorted into TIM-3 high cells and TIM-3 low cells. The cells were restimulated with PMA and A23187 and then CCL-1 transcription was determined by real-time RT-PCR. Although the induction pattern of CCL-1 showed difference among subjects, CCL-1 transcription was increased in TIM-3^high cells after stimulation in all subjects but not in TIM-3 low cells.

Taken together, these data suggest that CCL1 transcription may be enhanced in CD4⁺ T cells highly expressing TIM-3.

DISCUSSION

Presently, CCL1 was identified as a differentially expressed gene in CD4⁺ T cells highly expressing TIM-3 compared to cells with TIM-3 low expression. CCL1 is produced by both Th1 and Th2 cells in response to T cell receptor triggering (12). However, interleukin (IL)-12 and interferon (IFN)-alpha, cytokines that promote the differentiation of human Th1 cells selectively inhibit transcription and secretion of CCL1 by Th1 cells (12). In interferon-gamma knockout mice, CCL1 expression is increased along with the elevation of the Th2-associated chemokines CCL11 and CCL17, and the Th17-associated chemokines CCL22 and CXCL2 (13). Given that TIM-3 is preferentially expressed in fully differentiated Th1 cells, the increased CCL1 transcription by CD4⁺ T cells highly expressing TIM-3 was an unexpected result.

CCL1, originally identified as a gene expressed in activated T cell lines, is secreted by various cells including lymphocytes, Langerhans cells, monocytes, mast cells, endothelial cells and epithelial cells (14,15). Its sole receptor, CC chemokine receptor (CCR)-8, is expressed in polarized Th2 cells, IL-10 producing regulatory T cells and macrophages (16,17). Its chemotactic role for Th2 cells (16), and high serum levels in atopic dermatitis suggest that CCL1 plays a key role in the progression of Th2 type hypersensitivity (18,19). CCL1 together with CCL22 participates in the migration of regulatory T cells, leading to a reduced alloproliferative response (20,21). In mice, CCL1 interaction with CCR8 on macrophages leads to the development of postoperative and postinflammatory peritoneal adhesions (22). Further studies are required to investigate CCL1 production by TIM-3-expressing CD4⁺ T cells in normal and pathologic immune responses.

Currently, TIM-3 is believed to play a negative role in cytokine production by Th1 and Th17 cells based on the observations that the secretion of IFN-γ, IL-2, IL-17 and IL-6 by human CD4⁺ T cells is increased in the presence of anti-TIM-3 antibody (23), and that the cytokine production of Th1 cells is enhanced by the injection of TIM-3-Ig into mice (2). It will be interesting to examine whether the expression of other chemokines is affected by TIM3 expression and whether CCL1 expression is changed in the presence of anti-TIM-3 antibody.

In summary, TIM-3 expression in CD4⁺ T cells enhances transcription of CCL1, a chemotactic factor for CCR8⁺ polarized Th2 cells, regulatory T cells and macrophages.

Figures and Tables

Figure 1

TIM-3 expression in Jurkat T cell-derived stable cell clones. Jurkat T cell-derived stable cell clones expressing TIM3 and/or GFP were established. The cells were labeled with PE-conjugated antibody against TIM-3 and analyzed by flow cytometry.

Figure 2

Screening of differentially expressed genes between Jurkat T cells and TIM-3 expressing cell clone. RNA was isolated from Jurkat T cells and T5, a stable clone expressing TIM-3, stimulated with PMA (50 ng/ml) together with A23187 (0.5µM) for the indicated time, and then subjected to RT-PCR using the ACP system. The PCR product was analyzed by agarose gel electrophoresis. The primer sets used in PCR are indicated with ACP numbers and the differentially expressed candidate gene PCR products are indicated with arrows. Data are representative of the results from a total of 120 primer sets.

Figure 3

CCL1 transcript levels increase in TIM-3 expressing stable cells. RNA was isolated from Jurkat T cells, GFP expressing T cell clones (G2, G6) and TIM-3 expressing T cell clones (T5, T7) stimulated with PMA (50 ng/ml) together with A23187 (0.5µM) for 4 h and then subjected to semi-quantitative RT-PCR using specific gene primers for the indicated genes. Data are representative of two independent experiments. - unstimulated, + stimulated with PMA (P) and ionophore (I; A23187).

Figure 4

CCL1 transcript level increases in transiently transfected Jurkat T cells with TIM-3 expression vector. Jurkat T cells were transfected with TIM-3 expression plasmid (TIM-3) or empty control plasmid (Con V). Twenty four hours later, the cells were stimulated with PMA (50 ng/ml) together with A23187 (0.5µM) for 4 h and then subjected to semiquantitive RT-PCR using specific gene primers for the indicated genes. Data are mean±standard deviation of five independent experiments. P/I: PMA/A23187. ^*p<0.05.

Figure 5

CCL1 transcript levels increase in human primary CD4⁺ T cells expressing high level of TIM-3. Primary human CD4⁺ T cells were stimulated with antibodies against CD3 (1µg/ml) and CD28 (1 µg/ml) for 7 days and then sorted into TIM-3 ^high and TIM-3 ^low T cells, respectively. The cells were restimulated with PMA (50 ng/ml) together with A23187 (0.5µM) for the indicated time and then subjected to real-time RT-PCR for CCL1. Data are mean±standard deviation of triplicate. P/I: PMA/A23187.

Table I

Primers used for semiquantitive RT-PCR

Table II

Homologous genes to the differentially expressed transcripts.

ACKNOWLEDGEMENTS

This study was supported by a grant from a Korea Science and Engineering Foundation (KOSEF) grant (R13-2003-019) through The Chronic Inflammatory Disease Research Center (CIDRC), Ajou University. Ka Jung Jun was supported by The BK21 Program, Korean Ministry of Education.

Notes

The authors have no financial conflict of interest.

References

1. Anderson AC, Anderson DE. TIM-3 in autoimmunity. Curr Opin Immunol. 2006. 18:665–669.

2. Sabatos CA, Chakravarti S, Cha E, Schubart A, Sánchez-Fueyo A, Zheng XX, Coyle AJ, Strom TB, Freeman GJ, Kuchroo VK. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003. 4:1102–1110.

3. Lee MJ, Woo MY, Heo YM, Kim JS, Kwon MH, Kim K, Park S. The inhibition of the T-cell immunoglobulin and mucin domain 3 (Tim3) pathway enhances the efficacy of tumor vaccine. Biochem Biophys Res Commun. 2010. 402:88–93.

4. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel RA, Freeman GJ, Kuchroo VK. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002. 415:536–541.

5. Sánchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, Sabatos CA, Manlongat N, Bender O, Kamradt T, Kuchroo VK, Gutiérrez-Ramos JC, Coyle AJ, Strom TB. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol. 2003. 4:1093–1101.

6. Liu Y, Shu Q, Gao L, Hou N, Zhao D, Liu X, Zhang X, Xu L, Yue X, Zhu F, Guo C, Liang X, Ma C. Increased Tim-3 expression on peripheral lymphocytes from patients with rheumatoid arthritis negatively correlates with disease activity. Clin Immunol. 2010. 137:288–295.

7. Yang L, Anderson DE, Kuchroo J, Hafler DA. Lack of TIM-3 immunoregulation in multiple sclerosis. J Immunol. 2008. 180:4409–4414.

8. Morimoto K, Hosomi S, Yamagami H, Watanabe K, Kamata N, Sogawa M, Machida H, Okazaki H, Tanigawa T, Nagahara H, Noda E, Tominaga K, Watanabe T, Fujiwara Y, Maeda K, Hirakawa K, Arakawa T. Dysregulated upregulation of T-cell immunoglobulin and mucin domain-3 on mucosal T helper 1 cells in patients with Crohn's disease. Scand J Gastroenterol. 2011. 46:701–709.

9. Matsumoto R, Matsumoto H, Seki M, Hata M, Asano Y, Kanegasaki S, Stevens RL, Hirashima M. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem. 1998. 273:16976–16984.

10. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005. 6:1245–1252.

11. DeKruyff RH, Bu X, Ballesteros A, Santiago C, Chim YL, Lee HH, Karisola P, Pichavant M, Kaplan GG, Umetsu DT, Freeman GJ, Casasnovas JM. T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J Immunol. 2010. 184:1918–1930.

12. Iellem A, Colantonio L, Bhakta S, Sozzani S, Mantovani A, Sinigaglia F, D'Ambrosio D. Inhibition by IL-12 and IFN-alpha of I-309 and macrophage-derived chemokine production upon TCR triggering of human Th1 cells. Eur J Immunol. 2000. 30:1030–1039.

13. Su SB, Grajewski RS, Luger D, Agarwal RK, Silver PB, Tang J, Tuo J, Chan CC, Caspi RR. Altered chemokine profile associated with exacerbated autoimmune pathology under conditions of genetic interferon-gamma deficiency. Invest Ophthalmol Vis Sci. 2007. 48:4616–4625.

14. Selvan RS, Zhou LJ, Krangel MS. Regulation of I-309 gene expression in human monocytes by endogenous interleukin-1. Eur J Immunol. 1997. 27:687–694.

15. Gonzalo JA, Qiu Y, Lora JM, Al-Garawi A, Villeval JL, Boyce JA, Martinez-A C, Marquez G, Goya I, Hamid Q, Fraser CC, Picarella D, Cote-Sierra J, Hodge MR, Gutierrez-Ramos JC, Kolbeck R, Coyle AJ. Coordinated involvement of mast cells and T cells in allergic mucosal inflammation: critical role of the CC chemokine ligand 1:CCR8 axis. J Immunol. 2007. 179:1740–1750.

16. Zingoni A, Soto H, Hedrick JA, Stoppacciaro A, Storlazzi CT, Sinigaglia F, D'Ambrosio D, O'Garra A, Robinson D, Rocchi M, Santoni A, Zlotnik A, Napolitano M. The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J Immunol. 1998. 161:547–551.

17. Sebastiani S, Allavena P, Albanesi C, Nasorri F, Bianchi G, Traidl C, Sozzani S, Girolomoni G, Cavani A. Chemokine receptor expression and function in CD4+ T lymphocytes with regulatory activity. J Immunol. 2001. 166:996–1002.

18. Montes-Vizuet R, Vega-Miranda A, Valencia-Maqueda E, Negrete-García MC, Velásquez JR, Teran LM. CC chemokine ligand 1 is released into the airways of atopic asthmatics. Eur Respir J. 2006. 28:59–67.

19. Gombert M, Dieu-Nosjean MC, Winterberg F, Bünemann E, Kubitza RC, Da Cunha L, Haahtela A, Lehtimäki S, Müller A, Rieker J, Meller S, Pivarcsi A, Koreck A, Fridman WH, Zentgraf HW, Pavenstädt H, Amara A, Caux C, Kemeny L, Alenius H, Lauerma A, Ruzicka T, Zlotnik A, Homey B. CCL1-CCR8 interactions: an axis mediating the recruitment of T cells and Langerhans-type dendritic cells to sites of atopic skin inflammation. J Immunol. 2005. 174:5082–5091.

20. Soler D, Chapman TR, Poisson LR, Wang L, Cote-Sierra J, Ryan M, McDonald A, Badola S, Fedyk E, Coyle AJ, Hodge MR, Kolbeck R. CCR8 expression identifies CD4 memory T cells enriched for FOXP3+ regulatory and Th2 effector lymphocytes. J Immunol. 2006. 177:6940–6951.

21. Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, Sinigaglia F, D'Ambrosio D. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med. 2001. 194:847–853.

22. Hoshino A, Kawamura YI, Yasuhara M, Toyama-Sorimachi N, Yamamoto K, Matsukawa A, Lira SA, Dohi T. Inhibition of CCL1-CCR8 interaction prevents aggregation of macrophages and development of peritoneal adhesions. J Immunol. 2007. 178:5296–5304.

23. Hastings WD, Anderson DE, Kassam N, Koguchi K, Greenfield EA, Kent SC, Zheng XX, Strom TB, Hafler DA, Kuchroo VK. TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. Eur J Immunol. 2009. 39:2492–2501.